TEVA PHARMA INDUSTRIES LTD ADR

NYSE: TEVA (Teva Pharmaceutical Industries)

Last update: yesterday, 10:38AM

35.96

-0.29 (-0.80%)

  • 1D -0.80%
  • 5D 8.28%
  • 1M 16.00%
  • 6M 128.90%
  • YTD 16.19%
  • 1Y 108.95%
  • 5Y 193.79%
Previous Close 36.25
Open 36.18
Volume 2,836,258
Avg. Volume (3M) 11,776,652
Market Cap 41,256,280,064
Price / Earnings (TTM) 29.72
Price / Earnings (Forward) 11.20
Price / Sales 2.19
Price / Book 5.03
52 Weeks Range
12.47 (-65%) — 37.35 (3%)
Earnings Date 28 Jan 2026
Profit Margin -7.74%
Operating Margin (TTM) 18.22%
Diluted EPS (TTM) -1.15
Quarterly Revenue Growth (YOY) 1.90%
Total Debt/Equity (MRQ) 270.20%
Current Ratio (MRQ) 1.03
Operating Cash Flow (TTM) 1.27 B
Levered Free Cash Flow (TTM) 1.66 B
Return on Assets (TTM) 5.27%
Return on Equity (TTM) -19.11%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - Specialty & Generic (US) Mixed Bullish
Drug Manufacturers - Specialty & Generic (Global) Mixed Bullish
Stock Teva Pharmaceutical Industries Bullish Bullish

AIStockmoo Score

0.8
Analyst Consensus 1.5
Insider Activity NA
Price Volatility -3.0
Technical Moving Averages 2.5
Technical Oscillators 2.0
Average 0.75

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
TEVA 41 B - 29.72 5.03
TAK 56 B 4.61% 77.03 1.08
HLN 48 B 1.08% 23.51 2.08
RDY 12 B 54.73% 18.61 2.76
ZTS 56 B 0.79% 21.38 10.22
HIMS 6 B - 46.68 10.61

Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Investment Style Large Value
% Held by Institutions 67.15%

Ownership

Name Date Shares Held
Harel Insurance Investments & Financial Services Ltd. 31 Dec 2025 44,951,773
Phoenix Financial Ltd. 30 Sep 2025 41,295,244
Menora Mivtachim Holdings Ltd. 30 Sep 2025 38,920,294
Migdal Insurance & Financial Holdings Ltd. 31 Dec 2025 37,402,212
Clal Insurance Enterprises Holdings Ltd 30 Sep 2025 31,486,683
Lingotto Investment Management Llp 30 Sep 2025 28,588,790
Rubric Capital Management Lp 30 Sep 2025 24,650,000
Pointstate Capital Lp 30 Sep 2025 20,712,398
Glenview Capital Management, Llc 30 Sep 2025 16,692,680
Duquesne Family Office Llc 30 Sep 2025 16,593,935
Altshuler Shaham Ltd 30 Sep 2025 8,297,424
52 Weeks Range
12.47 (-65%) — 37.35 (3%)
Price Target Range
32.00 (-11%) — 40.00 (11%)
High 40.00 (Jefferies, 11.24%) Buy
40.00 (Scotiabank, 11.24%) Buy
40.00 (Piper Sandler, 11.24%) Buy
Median 38.00 (5.67%)
Low 32.00 (B of A Securities, -11.01%) Buy
Average 37.25 (3.59%)
Total 8 Buy
Avg. Price @ Call 31.57
Firm Date Target Price Call Price @ Call
Barclays 30 Jan 2026 38.00 (5.67%) Buy 34.08
09 Dec 2025 35.00 (-2.67%) Buy 28.56
Scotiabank 29 Jan 2026 40.00 (11.23%) Buy 33.07
05 Dec 2025 35.00 (-2.67%) Buy 28.46
Truist Securities 29 Jan 2026 38.00 (5.67%) Buy 33.07
Jefferies 06 Jan 2026 40.00 (11.23%) Buy 32.11
Piper Sandler 22 Dec 2025 40.00 (11.23%) Buy 31.21
Goldman Sachs 19 Dec 2025 35.00 (-2.67%) Buy 30.35
08 Dec 2025 31.00 (-13.79%) Buy 28.33
JP Morgan 16 Dec 2025 35.00 (-2.67%) Buy 30.10
06 Nov 2025 28.00 (-22.14%) Buy 24.46
B of A Securities 09 Dec 2025 32.00 (-11.01%) Buy 28.56
Show more

No data within this time range.

  • 3M
Date Type Details
28 Jan 2026 Announcement Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential
28 Jan 2026 Announcement Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential
27 Jan 2026 Announcement Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’
27 Jan 2026 Announcement Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’
14 Jan 2026 Announcement AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine
14 Jan 2026 Announcement AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine
11 Jan 2026 Announcement Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
11 Jan 2026 Announcement Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
11 Jan 2026 Announcement Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
11 Jan 2026 Announcement Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation
11 Jan 2026 Announcement Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation
07 Jan 2026 Announcement Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
05 Jan 2026 Announcement Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference
05 Jan 2026 Announcement Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference
24 Dec 2025 Announcement S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive
24 Dec 2025 Announcement S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive
23 Dec 2025 Announcement Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026
19 Dec 2025 Announcement Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
19 Dec 2025 Announcement Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
19 Dec 2025 Announcement Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
17 Dec 2025 Announcement Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA
16 Dec 2025 Announcement Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)
12 Dec 2025 Announcement Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026
12 Dec 2025 Announcement Teva Releases Q4 2025 Aide Memoire
12 Dec 2025 Announcement Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026
12 Dec 2025 Announcement Teva Releases Q4 2025 Aide Memoire
09 Dec 2025 Announcement Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
09 Dec 2025 Announcement Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
25 Nov 2025 Announcement Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference
25 Nov 2025 Announcement Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®
25 Nov 2025 Announcement Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®
21 Nov 2025 Announcement Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December
21 Nov 2025 Announcement Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December
19 Nov 2025 Announcement Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma’s Biggest Challenges
19 Nov 2025 Announcement Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma’s Biggest Challenges
12 Nov 2025 Announcement Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates
07 Nov 2025 Announcement AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living
07 Nov 2025 Announcement AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living
05 Nov 2025 Announcement Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS
05 Nov 2025 Announcement Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS
Show more
5Y Average Dividend Yield 0.00%
Ex Date Announcement Date Payment Date Details
27 Nov 2017 06 Nov 2017 12 Dec 2017 0.085 Cash
25 Aug 2017 - 14 Sep 2017 0.07225 Cash
01 Jun 2017 - 22 Jun 2017 0.289 Cash
28 Feb 2017 - 20 Mar 2017 0.289 Cash
01 Dec 2016 - 20 Dec 2016 0.289 Cash
18 Aug 2016 - 08 Sep 2016 0.289 Cash
20 May 2016 - 07 Jun 2016 0.289 Cash
25 Feb 2016 - 14 Mar 2016 0.289 Cash
13 Nov 2015 - 03 Dec 2015 0.289 Cash
18 Aug 2015 - 03 Sep 2015 0.289 Cash
15 May 2015 - 04 Jun 2015 0.289 Cash
17 Feb 2015 - 03 Mar 2015 0.293636 Cash
13 Nov 2014 - 02 Dec 2014 0.269593 Cash
19 Aug 2014 - 04 Sep 2014 0.291112 Cash
16 May 2014 - 02 Jun 2014 0.29777 Cash
20 Feb 2014 - 10 Mar 2014 0.293019 Cash
18 Nov 2013 - 03 Dec 2013 0.277541 Cash
16 Aug 2013 - 03 Sep 2013 0.273656 Cash
16 May 2013 - 03 Jun 2013 0.268249 Cash
19 Feb 2013 - 07 Mar 2013 0.266857 Cash
13 Nov 2012 - 03 Dec 2012 0.202399 Cash
13 Aug 2012 - 04 Sep 2012 0.208281 Cash
17 May 2012 - 04 Jun 2012 0.196042 Cash
23 Feb 2012 - 13 Mar 2012 0.197212 Cash
10 Nov 2011 - 07 Dec 2011 0.17539 Cash
09 Nov 2011 - 07 Dec 2011 0.171904 Cash
04 Aug 2011 - 25 Aug 2011 0.196304 Cash
03 Aug 2011 - 25 Aug 2011 0.199624 Cash
19 May 2011 - 07 Jun 2011 0.199925 Cash
10 Feb 2011 - 07 Mar 2011 0.216813 Cash
08 Nov 2010 - 06 Dec 2010 0.173008 Cash
02 Aug 2010 - 26 Aug 2010 0.166994 Cash
10 May 2010 - 04 Jun 2010 0.163153 Cash
19 Feb 2010 - 17 Mar 2010 0.164033 Cash
06 Nov 2009 - 04 Dec 2009 0.125431 Cash
03 Aug 2009 - 27 Aug 2009 0.124804 Cash
08 May 2009 - 03 Jun 2009 0.120261 Cash
23 Feb 2009 - 19 Mar 2009 0.111992 Cash
07 Nov 2008 - 05 Dec 2008 0.09309 Cash
01 Aug 2008 - 27 Aug 2008 0.10421 Cash
13 May 2008 - 05 Jun 2008 0.11255 Cash
12 May 2008 - 05 Jun 2008 0.10919 Cash
18 Feb 2008 - 13 Mar 2008 0.10429 Cash
15 Feb 2008 - 13 Mar 2008 0.10174 Cash
02 Nov 2007 - 28 Nov 2007 0.084 Cash
10 Aug 2007 - 06 Sep 2007 0.08015 Cash
10 May 2007 - 05 Jun 2007 0.0833 Cash
16 Feb 2007 - 15 Mar 2007 0.07866 Cash
10 Nov 2006 - 06 Dec 2006 0.06569 Cash
11 Aug 2006 - 08 Sep 2006 0.06434 Cash
12 May 2006 - 07 Jun 2006 0.06257 Cash
06 Mar 2006 - 30 Mar 2006 0.06072 Cash
10 Nov 2005 - 07 Dec 2005 0.05188 Cash
11 Aug 2005 - 07 Sep 2005 0.05431 Cash
05 May 2005 - 01 Jun 2005 0.0559 Cash
17 Feb 2005 - 17 Mar 2005 0.0559 Cash
09 Nov 2004 - 06 Dec 2004 0.0414 Cash
09 Aug 2004 - 07 Sep 2004 0.0401 Cash
10 May 2004 - 07 Jun 2004 0.0768 Cash
20 Feb 2004 - 22 Mar 2004 0.0781 Cash
13 Nov 2003 - 12 Dec 2003 0.0587 Cash
08 Aug 2003 - 08 Sep 2003 0.0596 Cash
08 May 2003 - 06 Jun 2003 0.0581 Cash
24 Feb 2003 - 24 Mar 2003 0.0546 Cash
07 Nov 2002 - 06 Dec 2002 0.0738 Cash
19 Aug 2002 - 16 Sep 2002 0.0738 Cash
20 May 2002 - 17 Jun 2002 0.0701 Cash
15 Feb 2002 - 18 Mar 2002 0.0772 Cash
16 Nov 2001 - 17 Dec 2001 0.0531 Cash
20 Aug 2001 - 17 Sep 2001 0.0498 Cash
17 May 2001 - 15 Jun 2001 0.0486 Cash
08 Mar 2001 - 06 Apr 2001 0.0477 Cash
16 Nov 2000 - 15 Dec 2000 0.0407 Cash
24 Aug 2000 - 21 Sep 2000 0.0415 Cash
19 May 2000 - 19 Jun 2000 0.0405 Cash
17 Feb 2000 - 27 Mar 2000 0.0838 Cash
04 Nov 1999 - 30 Nov 1999 0.0529 Cash
18 Aug 1999 - 13 Sep 1999 0.0527 Cash
21 May 1999 - 15 Jun 1999 0.054 Cash
08 Mar 1999 - 30 Mar 1999 0.055 Cash
20 Nov 1998 - 11 Dec 1998 0.053 Cash
21 Aug 1998 - 11 Sep 1998 0.058 Cash
21 May 1998 - 22 Jun 1998 0.0639 Cash
12 Mar 1998 - 31 Mar 1998 0.0649 Cash
20 Nov 1997 - 09 Dec 1997 0.0666 Cash
25 Aug 1997 - 11 Sep 1997 0.0667 Cash
23 May 1997 - 12 Jun 1997 0.069 Cash
07 Mar 1997 - 26 Mar 1997 0.0695 Cash
20 Nov 1996 - 09 Dec 1996 0.0468 Cash
26 Aug 1996 - 12 Sep 1996 0.0492 Cash
23 May 1996 - 12 Jun 1996 0.0477 Cash
07 Mar 1996 - 26 Mar 1996 0.0504 Cash
20 Nov 1995 - 07 Dec 1995 0.0485 Cash
14 Aug 1995 - 30 Aug 1995 0.0488 Cash
17 May 1995 - 07 Jun 1995 0.051 Cash
07 Mar 1995 - 04 Apr 1995 0.0512 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2017 0.735 4 3.88
2016 1.16 4 3.19
2015 1.16 4 1.77
2014 1.15 4 2.00
2013 1.09 4 2.71
2012 0.804 4 2.15
2011 1.16 6 2.87
2010 0.667 4 1.28
2009 0.482 4 0.86
2008 0.625 6 1.47
2007 0.326 4 0.70
2006 0.253 4 0.82
2005 0.218 4 0.51
2004 0.236 4 0.79
2003 0.231 4 0.82
2002 0.295 4 1.53
2001 0.199 4 1.29
2000 0.207 4 1.13
1999 0.215 4 2.40
1998 0.240 4 4.72
1997 0.272 4 4.60
1996 0.194 4 3.09
1995 0.200 4 3.44
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria